Want to see PCSA full AI Analyst Report?
Top Page
Processa Pharmaceuticals
(NASDAQ:PCSA)
Select Model
Select Model
Rating:42Neutral
Price Target:
$2.00
▲(1566.67% Upside)
Action:Reiterated
Date:06/12/26
The score is primarily constrained by weak financial performance driven by ongoing losses and significant cash burn, alongside a shrinking equity base. Technicals also remain soft with the stock trading below key moving averages and negative MACD. Valuation support is limited because the company is loss-making (negative P/E) and no dividend yield is available.
Positive Factors
Low leverage
Zero reported debt materially reduces refinancing and interest-rate risk and gives management structural flexibility to prioritize R&D and clinical timelines. Over the next several months this lowers mandatory cash outflows and preserves optionality for milestone-driven financing or partnerships.
Negative Factors
Heavy cash burn
Sustained negative operating and free cash flow at roughly -$15M TTM creates ongoing financing needs and raises the probability of dilutive capital raises. This structural cash consumption pressures R&D continuity and can force prioritization or delays absent milestone-driven funding or partner deals.
Read all positive and negative factors
Positive Factors
Negative Factors
Low leverage
Zero reported debt materially reduces refinancing and interest-rate risk and gives management structural flexibility to prioritize R&D and clinical timelines. Over the next several months this lowers mandatory cash outflows and preserves optionality for milestone-driven financing or partnerships.
Read all positive factors
Processa Pharmaceuticals (PCSA) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$5.98M
Dividend YieldN/A
Average Volume (3M)70.86K
Price to Earnings (P/E)―
Beta (1Y)0.29
Revenue GrowthN/A
EPS Growth86.07%
CountryUS
Employees10
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-10.66
Shares Outstanding2,768,032
10 Day Avg. Volume74,545
30 Day Avg. Volume70,864
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.68
Price to Sales (P/S)0.00
P/FCF Ratio-0.33
Enterprise Value/Market Cap0.53
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-10.57K
Enterprise Value/Ebitda-0.23
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-6
Revenue Forecast (FY)$10.01M
Processa Pharmaceuticals Business Overview & Revenue Model
Company Description
Processa Pharmaceuticals, Inc. is a biopharmaceutical company in the clinical development stage, committed to identifying and progressing therapeutic agents for patients with critical unmet medical requirements throughout the United States. The co...
How the Company Makes Money
null...
Processa Pharmaceuticals Financial Statement Overview
Summary
Income Statement
6
Very Negative
Balance Sheet
38
Negative
Cash Flow
12
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -301.00 | 0.00 | 0.00 | 0.00 | -874.01K | 0.00 |
| EBITDA | -14.11M | -13.56M | -11.85M | -11.12M | -26.64M | -10.78M |
| Net Income | -14.11M | -13.56M | -11.85M | -11.12M | -27.42M | -11.43M |
Balance Sheet | ||||||
| Total Assets | 4.52M | 7.81M | 3.23M | 5.79M | 8.62M | 26.46M |
| Cash, Cash Equivalents and Short-Term Investments | 1.69M | 5.54M | 1.19M | 4.71M | 6.50M | 16.50M |
| Total Debt | 0.00 | 0.00 | 73.51K | 150.55K | 229.45K | 78.46K |
| Total Liabilities | 1.98M | 2.24M | 1.53M | 797.48K | 1.15M | 978.40K |
| Stockholders Equity | 2.54M | 5.58M | 1.70M | 4.99M | 7.47M | 25.49M |
Cash Flow | ||||||
| Free Cash Flow | -12.25M | -11.39M | -11.25M | -8.07M | -9.61M | -8.72M |
| Operating Cash Flow | -12.25M | -11.39M | -11.25M | -8.06M | -9.61M | -8.72M |
| Investing Cash Flow | -1.35M | -850.00K | -3.24K | -2.78K | 0.00 | 0.00 |
| Financing Cash Flow | 12.39M | 16.58M | 7.73M | 6.27M | -388.84K | 9.80M |
Processa Pharmaceuticals Technical Analysis
Neutral
0.12
Price Trends
2.49
Negative
2.54
Negative
4.17
Negative
Market Momentum
-0.15
Negative
48.16
Neutral
37.43
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PCSA, the sentiment is Neutral. The current price of 0.12 is below the 20-day moving average (MA) of 2.13, below the 50-day MA of 2.49, and below the 200-day MA of 4.17, indicating a neutral trend. The MACD of -0.15 indicates Negative momentum. The RSI at 48.16 is Neutral, neither overbought nor oversold. The STOCH value of 37.43 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for PCSA.
Processa Pharmaceuticals Risk Analysis
Processa Pharmaceuticals disclosed 41 risk factors in its most recent earnings report. Processa Pharmaceuticals reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Processa Pharmaceuticals Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
45 Neutral | $19.70M | -1.22 | -66.69% | ― | -45.52% | -94.82% | |
45 Neutral | $14.34M | -1.41 | -94.94% | ― | ― | 53.06% | |
45 Neutral | $3.76M | -0.01 | -154.50% | ― | ― | -92.20% | |
42 Neutral | $5.98M | -0.20 | -281.30% | ― | ― | 86.07% | |
41 Neutral | $9.28M | -982.29 | ― | ― | ― | ― | |
41 Neutral | $5.74M | -0.20 | -246.04% | ― | ― | 54.48% |
* Healthcare Sector Average
PCSA
Processa Pharmaceuticals
2.16
-2.71
-55.65%
CANF
Can-Fite BioPharma
3.91
-16.49
-80.83%
SNGX
Soligenix
0.39
-0.81
-67.75%
LPCN
Lipocine
2.39
-0.71
-22.90%
COCP
Cocrystal Pharma
1.04
-0.48
-31.58%
PHGE
BiomX
0.32
-8.04
-96.18%
Processa Pharmaceuticals Corporate Events
Business Operations and StrategyExecutive/Board ChangesRegulatory Filings and Compliance
Processa Pharmaceuticals Announces Transition of Chief Development Officer
Neutral
Apr 30, 2026
On April 30, 2026, Processa Pharmaceuticals approved a planned transition toward retirement for Dr. Sian Bigora, its Chief Development and Regulatory Officer. Effective May 1, 2026, she moved from a full-time executive officer role to a part-time ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.